Letvimo Capsules 40mg, from Eli Lilly Japan, contains Selpercatinib (YJ code: 4291075M1027, standard: 40mg 1 capsule). This medication is a selective RET kinase inhibitor that targets RET gene fusions and mutations, which are oncogenic drivers in various cancers. By inhibiting the RET receptor kinase, it blocks growth signals and prevents cancer cell division.
Letvimo Capsules 40mg
Need more detailed information?
Contact TASAKI PHARMA for product sourcing, availability, or related support (English support available).
